Phibro Animal Health Corporation (NASDAQ:PAHC) had its price target upped by Credit Suisse Group from $36.00 to $37.00 in a research report report published on Thursday. Credit Suisse Group currently has an outperform rating on the stock.

Several other brokerages have also commented on PAHC. BidaskClub lowered Phibro Animal Health Corporation from a strong-buy rating to a buy rating in a research note on Wednesday, August 23rd. Bank of America Corporation reaffirmed an underperform rating and issued a $33.00 price target on shares of Phibro Animal Health Corporation in a research note on Wednesday, August 23rd. Piper Jaffray Companies set a $35.00 price target on Phibro Animal Health Corporation and gave the company a buy rating in a research note on Friday, July 21st. Finally, Zacks Investment Research raised Phibro Animal Health Corporation from a hold rating to a buy rating and set a $38.00 price target on the stock in a research note on Thursday, May 11th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $32.00.

Phibro Animal Health Corporation (NASDAQ:PAHC) traded up 2.68% during midday trading on Thursday, reaching $36.35. The company’s stock had a trading volume of 103,259 shares. The firm has a 50 day moving average price of $38.57 and a 200 day moving average price of $33.30. The firm has a market capitalization of $1.44 billion, a PE ratio of 22.58 and a beta of 1.35. Phibro Animal Health Corporation has a 1-year low of $24.83 and a 1-year high of $40.25.

Phibro Animal Health Corporation (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $0.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.04. The business had revenue of $194.84 million for the quarter, compared to analyst estimates of $192.47 million. Phibro Animal Health Corporation had a return on equity of 51.23% and a net margin of 8.45%. Phibro Animal Health Corporation’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 EPS. On average, analysts predict that Phibro Animal Health Corporation will post $1.54 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/01/phibro-animal-health-corporation-pahc-given-new-37-00-price-target-at-credit-suisse-group.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 27th. Shareholders of record on Wednesday, September 6th will be paid a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Friday, September 1st. Phibro Animal Health Corporation’s dividend payout ratio is currently 24.69%.

In other Phibro Animal Health Corporation news, VP Daniel M. Bendheim sold 5,938 shares of the business’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $40.04, for a total value of $237,757.52. Following the transaction, the vice president now owns 300 shares of the company’s stock, valued at $12,012. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Daniel M. Bendheim sold 1,443 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $40.05, for a total value of $57,792.15. Following the completion of the transaction, the vice president now directly owns 300 shares in the company, valued at approximately $12,015. The disclosure for this sale can be found here. In the last three months, insiders sold 268,657 shares of company stock worth $9,802,503. Insiders own 48.09% of the company’s stock.

Several institutional investors have recently modified their holdings of PAHC. Janus Henderson Group PLC purchased a new position in shares of Phibro Animal Health Corporation during the second quarter valued at about $6,353,000. AJO LP purchased a new position in shares of Phibro Animal Health Corporation during the second quarter valued at about $5,815,000. FMR LLC raised its position in shares of Phibro Animal Health Corporation by 31.9% in the second quarter. FMR LLC now owns 584,463 shares of the company’s stock valued at $21,654,000 after buying an additional 141,274 shares during the period. Vanguard Group Inc. raised its position in shares of Phibro Animal Health Corporation by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,729,406 shares of the company’s stock valued at $48,597,000 after buying an additional 130,935 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Phibro Animal Health Corporation by 50.6% in the second quarter. Ameriprise Financial Inc. now owns 339,996 shares of the company’s stock valued at $12,599,000 after buying an additional 114,230 shares during the period. 48.35% of the stock is currently owned by institutional investors and hedge funds.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Analyst Recommendations for Phibro Animal Health Corporation (NASDAQ:PAHC)

Receive News & Stock Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related stocks with our FREE daily email newsletter.